Patents Examined by Erinne R Dabkowski
  • Patent number: 10463711
    Abstract: Nutritive polypeptides are provided herein. Also provided are various other embodiments including nucleic acids encoding the polypeptides, recombinant microorganisms that make the polypeptides, vectors for expressing the polypeptides, methods of making the polypeptides using recombinant microorganisms, compositions and formulations that comprise the polypeptides, and methods of using the polypeptides, compositions and formulations.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: November 5, 2019
    Assignee: Axcella Health Inc.
    Inventors: Michael Hamill, Brett Boghigian, Caitlyn Harvey, David Berry, David Young, Geoffrey Von Maltzahn, John Kramarczyk, Jameson Rogers, Kathryn Heard, Michael Doherty, Nathaniel Silver, Phillip Samayoa, Subhayu Basu, Shaila Rahman, Vimal Vaidya, Ying-Ja Chen
  • Patent number: 10441627
    Abstract: This disclosure relates to a method of treating Prader-Willi Syndrome. The method includes administering to a patient in need thereof an effective amount of a composition containing a selective oxytocin receptor agonist or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: October 15, 2019
    Assignee: FERRING B.V.
    Inventors: Pascal Danglas, Michael Reidy, Paul Korner, Sudarkodi Alagarsamy
  • Patent number: 10434137
    Abstract: The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the the proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, including peptides and/or interfering RNA and/or lipidic compounds, the agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: October 8, 2019
    Assignee: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA
    Inventors: Celia Berta Fernandez Ortega, Anna Caridys Ramírez Suarez, Dionne Casillas Casanova, Taimi Emelia Paneque Guerrero, Raimundo Ubieta Gomez, Marta Dubed Echevarria, Leonor Margarita Navea Leyva, Lila Rosa Castellanos Serra, Carlos Antonio Duarte Cano, Viviana Falcon Cama, Osvaldo Reyes Acosta
  • Patent number: 10426813
    Abstract: The present invention relates to a method of enhancing endurance of a human subject through administration of alanyl-glutamine or alanyl-glutamine salt. The invention includes unexpected discovery of alanyl-glutamine or alanyl-glutamine salt enhancing durability and endurance of human subject independent of an increase in the blood glutamine level.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: October 1, 2019
    Assignee: KYOWA HAKKO BIO CO., LTD.
    Inventors: Masayuki Ochiai, Koji Morishita, Miho Komatsu, Kentaro Sugimura
  • Patent number: 10428125
    Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: October 1, 2019
    Assignee: Genentech, Inc.
    Inventors: Rami Hannoush, Harini Kaluarachchi, Aaron Nile, Cameron Noland, Yingnan Zhang, Lijuan Zhou, Xinxin Gao
  • Patent number: 10420783
    Abstract: The present invention relates to a foodstuff comprising feather hydrolysate for use in improving performance during exercise and/or improving recovery after exercise in a dog. It also relates to a method of improving the performance in a dog during exercise and/or improving recovery after exercise, the method comprising administering to a dog a foodstuff which comprises feather hydrolysate.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: September 24, 2019
    Assignee: Mars, Incorporated
    Inventors: Alexandre Feugier, Delphine Clero
  • Patent number: 10414799
    Abstract: The present invention provides peptide compounds that regulate the complement system and methods of using these compounds. The invention is an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of CP1 having, for example, internal peptide deletions and substitutions, deletions and substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The invention further provides pharmaceutical compositions of therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: September 17, 2019
    Assignee: ReAlta Holdings, LLC
    Inventors: Neel K. Krishna, Kenji Cunnion
  • Patent number: 10406230
    Abstract: The present disclosure relates to an exendin-4 analog PEGylated with polyethylene glycol or a derivative thereof, a preparation method, and a pharmaceutical composition for prevention or treatment of diabetes containing the same as an active ingredient. According to the present invention, the yield of an exendin-4 analog can be increased via the selective PEGylation by using exendin-4 in which a cysteine is introduced into #40 site of the C-terminal, and treatment effect of medications can be increased, so that the exendin-4 analog can be usefully applied as a composition for prevention or treatment of diseases caused by insulin hypersecretion.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: September 10, 2019
    Assignee: D&D Pharmatech Inc.
    Inventors: Sung Kwon Lee, Won Bae Kim, Seulki Lee, Tae Hyung Kim
  • Patent number: 10407483
    Abstract: A process is described for purifying insulin and insulin analogs that comprises high-pressure liquid chromatography with an acidic cation exchange medium performed in the presence of a water miscible organic modifier and at an elevated temperature followed by reverse phase chromatography performed in the presence of a water miscible organic modifier and at an elevated temperature.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: September 10, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Allison D. Ortigosa, Michael P. Coleman, Shibu T. George, Michael A. Rauscher, Mark C. Sleevi, Kartoa Chow
  • Patent number: 10400022
    Abstract: A peptide that binds specifically to neuropilin-1 (NRP1) without binding to neuropilin-2 (NRP2) is provided. A fusion protein, a fusion antibody, small-molecule drug, a nanoparticle, or a liposome, which comprises the peptide, and a pharmaceutical composition for treating or preventing cancer or angiogenesis-related diseases, and a composition for diagnosing cancer or angiogenesis-related diseases are provided. A polynucleotide encoding the peptide that binds specifically to NRP1 and a method for screening the peptide that binds specifically to NRP1 are provided. An antibody heavy-chain constant region Fc-fused peptide binding specifically to NRP1 has the property of binding specifically to NRP1, and thus when it is administered in vivo, it accumulates selectively in tumor tissue, and widens the intercellular space between tumor-associated endothelial cells to promote its extravasation and increases its tumor tissue penetration.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: September 3, 2019
    Assignee: Ajou University Industry-Academic Cooperation Foundation
    Inventors: Yong Sung Kim, Ye Jin Kim
  • Patent number: 10398752
    Abstract: The present disclosure describes to a method of treating a metabolic disease in a subject, wherein the method comprises administration of dermatopontin to a subject, wherein the dermatopontin is recombinant dermatopontin and the metabolic disease is selected from a group consisting of weight gain, diet-induced weight gain, obesity, morbid obesity, metabolic syndrome, glucose homeostasis, insulin resistance, type I diabetes, type if diabetes and cardiovascular disease.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: September 3, 2019
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Wanjin Hong, Shixiong Tan, Weiping Han
  • Patent number: 10391143
    Abstract: MOTS3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using MOTS3 and pharmaceutical compositions thereof are disclosed herein.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: August 27, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Pinchas Cohen, Changhan Lee
  • Patent number: 10385104
    Abstract: The present invention relates to peptides comprising analogues of VDAC1-derived peptides having improved pharmacokinetic characteristics compared to the native parent peptides, which are effective in impairing cell energy production, in inducing apoptosis and cell death, particularly of cancerous cells, in eliminating cancer stem cells and in reducing symptoms associated with fat accumulation in liver cells particularly with nonalcoholic fatty liver disease (NAFLD) and symptoms associated thereto.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: August 20, 2019
    Assignees: B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY, THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD.
    Inventor: Varda Shoshan-Barmatz
  • Patent number: 10369195
    Abstract: Provided herein are methods and compositions for preventing and treating damage to the heart subsequent to myocardial infarction (MI) resulting from harmful fibrotic remodeling, thereby improving cardiac function and reducing mortality from subsequent heart failure.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: August 6, 2019
    Assignees: MandalMed, Inc., The Regents of the University of California
    Inventors: Constance M. John, Meenakshi Gaur, Matthew L. Springer, Xiaoyin Wang
  • Patent number: 10342850
    Abstract: The present invention relates to a sterile solution comprising: octreotide in the form of a pharmaceutically acceptable salt, present at a concentration equivalent to 2.0 mg/ml to 2.5 mg/ml of octreotide base, and at least one preservative in a pharmaceutically acceptable vehicle, wherein the sterile solution is present in an injection device.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: July 9, 2019
    Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Amar Rana, Rakesh Thummar, Sudeep Agrawal, Subhas Balaram Bhowmick, Rajamannar Thennati
  • Patent number: 10342847
    Abstract: The present invention relates to compositions and methods for preventing and reducing inflammation and preventing and treating diseases and disorders associated with inflammation. It has been shown that CRADD plays a pivotal role in maintaining the integrity of endothelial monolayers. The recombinant cell-penetrating CRADD protein (CP-CRADD)-based compositions and methods described herein provide for the development of a novel treatment for inflammatory vascular disorders including cardiovascular, cerebrovascular, respiratory, gastrointestinal, and renal systems.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: July 9, 2019
    Assignee: Vanderbilt University
    Inventors: Jack J. Hawiger, Ruth Ann Veach, Yan Liu, Huan Qiao, Lukasz S. Wylezinski
  • Patent number: 10328156
    Abstract: Compositions and methods are provided including a transporter peptide derived from the loop2 domain of the neuronally-derived lynx1 protein which can be conjugated to an effector agent to form a transporter-effector complex for transport of the therapeutic effector agent to a target that is found across the blood brain barrier.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: June 25, 2019
    Assignee: OPHIDION INC.
    Inventor: Andreas Walz
  • Patent number: 10329331
    Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for treatment or diagnosis of disease in mammals including humans.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: June 25, 2019
    Assignee: AFFIBODY AB
    Inventors: Caroline Ekblad, Lars Abrahmsen
  • Patent number: 10314888
    Abstract: The invention relates to therapeutic and cosmetic uses of calreticulin including reducing or eliminating wrinkles and/or fine lines, tissue repair and reconstruction, repairing damaged bone and/or cartilage, stimulating regeneration of an epidermal appendage, enhancing phagocytosis of bacteria by phagocytes within a wound, treating a wound in a patient suffering from delayed wound healing, treating a corneal wound, and treating or preventing a surgical adhesion.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: June 11, 2019
    Assignee: New York University
    Inventors: Leslie I. Gold, Marek Michalak
  • Patent number: 10314893
    Abstract: Emerging evidence indicates that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin converting enzyme2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to pulmonary hypertension (PH). However, clinical success for long-term delivery of ACE2 or Ang-(1-7) would require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastric enzymes; fusion to a transmucosal carrier facilitates effective systemic absorption. Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) attenuated monocrotaline (MCT)-induced increase in right ventricular systolic pressure, decreased pulmonary vessel wall thickness and improved right heart function in both prevention and reversal protocols.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: June 11, 2019
    Assignees: The Trustees of the University of Pennsylvania, University of Florida Research Foundation, Incorporated
    Inventors: Henry Daniell, Qiuhong Li, Mohan K. Raizada